• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 9-23 of 68 results

6 Preliminary Response: Patent Owner Preliminary Response

Document IPR2021-01132, No. 6 Preliminary Response - Patent Owner Preliminary Response (P.T.A.B. Oct. 12, 2021)
Paper No. 6 Filed: October 12, 2021 Introduction The Board should deny institution under 35 U.S.C. § 325(d) because the Petition recycles the same prior art and arguments considered by the Examiner during prosecution of the ’927 patent.
Paper No. 6 Filed: October 12, 2021 (“Compounds that bind to neuronal nicotinic receptor sites, including [varenicline], and its hydrochloride salt, are referred to in WO 99/35131 [i.e., Coe], published Jul.
Despite Petitioner’s assertions to the contrary, a plain reading of the prosecution history leaves no doubt that the Examiner evaluated the precise arguments that Petitioner Paper No. 6 Filed: October 12, 2021 now raises.
As discussed above, this type of broad overview does not “add significantly to the information considered by the Examiner during prosecution,” Canon Inc., IPR2016-01202, Paper 15 at 13, and does not shift factor (c) in favor of institution.
Nor does Pfizer demonstrate the Examiner erred in allowing the challenged claims here, as there is no evidence (either in the file history or cited in the Petition) that would have led a POSA to the tartrate salt of varenicline.
cite Cite Document
Analyze

3 Mandatory Notice: Patent Owners Mandatory Notices

Document IPR2021-01132, No. 3 Mandatory Notice - Patent Owners Mandatory Notices (P.T.A.B. Jul. 7, 2021)
Log in to see more
cite Cite Document
Analyze

2 Power of Attorney: Petitioners Power of Attorney

Document IPR2021-01132, No. 2 Power of Attorney - Petitioners Power of Attorney (P.T.A.B. Jun. 17, 2021)
Log in to see more
cite Cite Document
Analyze

2002 Exhibit: 503 Patent

Document IPR2021-01132, No. 2002-27 Exhibit - 503 Patent (P.T.A.B. Oct. 12, 2021)
Log in to see more
cite Cite Document
Analyze

2001 Exhibit: Chantix Label

Document IPR2021-01132, No. 2001-26 Exhibit - Chantix Label (P.T.A.B. Oct. 12, 2021)
Log in to see more
cite Cite Document
Analyze

2004 Exhibit: PubChem Robalzotan

Document IPR2021-01132, No. 2004-29 Exhibit - PubChem Robalzotan (P.T.A.B. Oct. 12, 2021)

cite Cite Document
Analyze

2003 Exhibit: EP1078637A2

Document IPR2021-01132, No. 2003-28 Exhibit - EP1078637A2 (P.T.A.B. Oct. 12, 2021)

cite Cite Document
Analyze

2004 Exhibit: PubChem Robalzotan

Document IPR2021-01132, No. 2004 Exhibit - PubChem Robalzotan (P.T.A.B. Oct. 12, 2021)

cite Cite Document
Analyze

2002 Exhibit: 503 Patent

Document IPR2021-01132, No. 2002 Exhibit - 503 Patent (P.T.A.B. Oct. 12, 2021)

cite Cite Document
Analyze

2003 Exhibit: EP1078637A2

Document IPR2021-01132, No. 2003 Exhibit - EP1078637A2 (P.T.A.B. Oct. 12, 2021)

cite Cite Document
Analyze

2001 Exhibit: Chantix Label

Document IPR2021-01132, No. 2001 Exhibit - Chantix Label (P.T.A.B. Oct. 12, 2021)

cite Cite Document
Analyze

1021 Exhibit: Ex 1021 US 6794388

Document IPR2021-01132, No. 1021-22 Exhibit - Ex 1021 US 6794388 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1017 Exhibit: Ex 1017 Jessen

Document IPR2021-01132, No. 1017-18 Exhibit - Ex 1017 Jessen (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1003 Exhibit: Ex 1003 Gould CV

Document IPR2021-01132, No. 1003-3 Exhibit - Ex 1003 Gould CV (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1004 Exhibit: Ex 1004 927 PH

Document IPR2021-01132, No. 1004-4 Exhibit - Ex 1004 927 PH (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze
<< 1 2 3 4 5 >>